Cardinal Health, Inc. Common Stock (CAH) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
74/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$224.94
Trend Context
Mixed / range
Latest briefing
What's happening with CAH
prnewswire.com9 Jul 2026
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
fool.com6 Jul 2026
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com3 Jul 2026
Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating
Cardinal Health receives a Buy rating, supported by defensive business fundamentals, strong adjusted EPS growth, and strategic expansion into specialty healthcare. CAH's Q3FY26 showed 11% revenue growth and 35% adjusted EPS growth, though GAAP results were pressured by higher costs and special items. Valuation is at a premium with a Forward P/E of 21.64x, justified by improving profitability and cash flow, but future upside depends on sustained margin gains.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
